Thus, it is clear that the combination of osimertinib with MEK inhibition restores the induction of apoptosis accompanied with an early downregulation of DR4 in osimertinib-resistant NSCLC cells. This evidence concerns the gene TNFRSF10A and non-small cell lung carcinoma.